2023
Role of Inflammatory Processes in Hemorrhagic Stroke
Ohashi S, DeLong J, Kozberg M, Mazur-Hart D, van Veluw S, Alkayed N, Sansing L. Role of Inflammatory Processes in Hemorrhagic Stroke. Stroke 2023, 54: 605-619. PMID: 36601948, DOI: 10.1161/strokeaha.122.037155.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHemorrhagic strokeIntracerebral hemorrhageInflammatory processCerebral amyloid angiopathy-related haemorrhageAngiopathy-related hemorrhageRole of inflammationCerebral amyloid angiopathyInflammatory immune responseEffective therapeutic strategyCentral nervous systemBrain residentAmyloid angiopathyImmune cellsTissue injuryCommon causeImmune responseHemorrhageTherapeutic strategiesNervous systemMajor subtypesDisease pathologyStrokeOlder individualsTissue recoveryDeadliest form
2022
Inflammatory Responses After Ischemic Stroke
DeLong JH, Ohashi SN, O’Connor K, Sansing LH. Inflammatory Responses After Ischemic Stroke. Seminars In Immunopathology 2022, 44: 625-648. PMID: 35767089, DOI: 10.1007/s00281-022-00943-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Leukocyte dynamics after intracerebral hemorrhage in a living patient reveal rapid adaptations to tissue milieu
Goods BA, Askenase MH, Markarian E, Beatty HE, Drake RS, Fleming I, DeLong JH, Philip NH, Matouk CC, Awad IA, Zuccarello M, Hanley DF, Love JC, Shalek AK, Sansing LH, Investigators T. Leukocyte dynamics after intracerebral hemorrhage in a living patient reveal rapid adaptations to tissue milieu. JCI Insight 2021, 6: e145857. PMID: 33749664, PMCID: PMC8026179, DOI: 10.1172/jci.insight.145857.Peer-Reviewed Original ResearchConceptsIntracerebral hemorrhageAcute brain injurySystemic immune responsesBrain tissue injuryHigh mortality rateLocal cellular responseAcute injuryTreatment optionsIntracerebral eventsBrain injuryCerebral hematomaLeukocyte responseTissue injuryT cellsImmune responseCT scanMortality rateDevastating formImmune dynamicsTherapeutic interventionsLeukocyte dynamicsBrain tissuePatientsInvasive surgeryInjury
2017
IL-27 LIMITS TYPE 2 IMMUNOPATHOLOGY FOLLOWING PARAINFLUENZA VIRUS INFECTION
Muallem G, Wagage S, Sun Y, DeLong JH, Valenzuela A, Christian DA, Pritchard G, Fang Q, Buza EL, Jain D, Elloso MM, López CB, Hunter CA. IL-27 LIMITS TYPE 2 IMMUNOPATHOLOGY FOLLOWING PARAINFLUENZA VIRUS INFECTION. PLOS Pathogens 2017, 13: e1006173. PMID: 28129374, PMCID: PMC5305264, DOI: 10.1371/journal.ppat.1006173.Peer-Reviewed Original ResearchConceptsParainfluenza virus infectionTh2 responsesIL-27Control miceT cellsVirus infectionParamyxovirus infectionDisease severityWeight lossPathogenic Th2 responsesQuality of CD4Type 2 immunopathologyT-cell depletionT cell responsesSevere lung lesionsPopulation of IFNParainfluenza infectionsPulmonary eosinophilsRespiratory paramyxovirusesT helperCell depletionLung lesionsImmune responseLimit pathologyCD4
2011
Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy
Wambre E, DeLong JH, James EA, LaFond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. Journal Of Allergy And Clinical Immunology 2011, 129: 544-551.e7. PMID: 21975176, PMCID: PMC3268867, DOI: 10.1016/j.jaci.2011.08.034.Peer-Reviewed Original ResearchConceptsNonallergic subjectsT cellsPollen allergyPeptide-MHC class II tetramersAllergen-specific T cellsChemoattractant receptor-homologous moleculeAllergen-specific CD4Natural pollen exposureAllergen-specific immunotherapyClass II tetramersProtective immune responseT cell outcomesIL-10 inductionLymphocyte expressionSpecific immunotherapyIL-10Allergic subjectsAllergy vaccinationCytokine productionImmune responseDifferentiation stageSeasonal allergiesPollen exposureAllergyProtective response